Bristol-Myers Squibb Co vs Invesco S&P 500 Momentum ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.66 (market cap $129.94B), while Invesco S&P 500 Momentum ETF trades at $150. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Invesco S&P 500 Momentum ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Invesco S&P 500 Momentum ETF nearer its low. Which is the better fit depends on your goals.
| BMY | SPMO | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $65.89 | $161.66 |
52-Week Low | $42.60 | $107.84 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →